Organon & Co
USUSDOrganon & Co (LSE:0A9W) — Biotechnology: Pharmaceutical Preparations. Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 2. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.
Apie Įmonę
- Svetainė
- organon.com
- Investuotojams
- organon.com/investor-relations/
- Sektorius
- Health Care · Biotechnology: Pharmaceutical Preparations
- Būstinė
- Oss, United States
- Generalinis Direktorius
- Joseph T. Morrissey
- Darbuotojai
- 10 000
- Įkurta
- 1923
- Apyvartoje Esančios Akcijos
- Laisvai Apyvartinės Akcijos
- 242.99 mln.
- Rinkos Kapitalizacija
- 3.6 mlrd. USD
- Insaideriai
- 0.46%
- Instituciniai Investuotojai
- 84.8%
- Šaka (SIC)
- Pharmaceutical Preparations
- ISIN
- US68622V1061
- LEI
- 549300AMCKY57OK2CO56
- Išmokų Santykis
- 8.6%
- FCF
- 567 mln. USD
- Išmokėjimas / FCF
- 3%
- Skola
- 8.55 mlrd. USD13 m. FCF
- Dividendų Stažas
- 5 m.
- Pelnas, FCF ir dividendai – už 12 mėnesių iki 30.06.2026 (naujausia įmonės ataskaita).
- NAV
Aprašymas
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Dividendai
Organon & Co (0A9W) moka dividendus kas ketvirtį. Per metus (12 mėnesių iki ir įskaitant naujausią paskelbtą mokėjimą): 0.08 USD už akciją (mokėjimai: 4). Tai sudaro apie 0.58% dabartinės akcijų kainos. Pagal išmokų istoriją kita ex-dividendų data tikėtina apie 17.11.2026. Nepertraukiamų dividendų metai: 5.
| Ex Data | Išmoka | Suma | % | Tipas | Tikeris |
|---|---|---|---|---|---|
| 2026-08-14 | 2026-09-10 | 0.0200 USD | 0.1/0.6 % | kas ketvirtį | LSE:0A9W |
| 2026-05-11 | 2026-06-11 | 0.0200 USD | 0.2/0.6 % | kas ketvirtį | LSE:0A9W |
| 2026-02-23 | 2026-03-12 | 0.0200 USD | 0.3/1.0 % | kas ketvirtį | LSE:0A9W |
| 2025-11-20 | 2025-12-11 | 0.0200 USD | 0.3/4.6 % | kas ketvirtį | LSE:0A9W |
| 2025-08-15 | 2025-09-11 | 0.0200 USD | 0.2/6.5 % | kas ketvirtį | LSE:0A9W |
| 2025-05-12 | 2025-06-12 | 0.0200 USD | 0.2/9.7 % | kas ketvirtį | LSE:0A9W |
| 2025-02-21 | 2025-03-13 | 0.2800 USD | 1.8/7.2 % | kas ketvirtį | LSE:0A9W |
| 2024-11-12 | 2024-12-12 | 0.2800 USD | 1.5/6.0 % | kas ketvirtį | LSE:0A9W |
| 2024-08-16 | 2024-09-12 | 0.2800 USD | 1.5/6.0 % | kas ketvirtį | LSE:0A9W |
| 2024-05-10 | 2024-06-13 | 0.2800 USD | 1.5/6.0 % | kas ketvirtį | LSE:0A9W |
| 2024-02-23 | 2024-03-14 | 0.2800 USD | 1.5/6.0 % | kas ketvirtį | LSE:0A9W |
| 2023-11-10 | 2023-12-14 | 0.2800 USD | 2.4/9.8 % | kas ketvirtį | LSE:0A9W |
| 2023-08-17 | — | 0.2800 USD | 1.2/4.9 % | kas ketvirtį | LSE:0A9W |
| 2023-05-12 | — | 0.2800 USD | 1.3/5.3 % | kas ketvirtį | LSE:0A9W |
| 2023-02-24 | — | 0.2800 USD | 1.1/4.2 % | kas ketvirtį | LSE:0A9W |
| 2022-11-10 | — | 0.2800 USD | 1.2/4.7 % | kas ketvirtį | LSE:0A9W |
| 2022-08-12 | — | 0.2800 USD | 0.9/3.5 % | kas ketvirtį | LSE:0A9W |
| 2022-05-13 | — | 0.2800 USD | 0.8/2.4 % | kas ketvirtį | LSE:0A9W |
| 2022-02-25 | — | 0.2800 USD | 0.8/1.6 % | kas ketvirtį | LSE:0A9W |
| 2021-11-19 | — | 0.2800 USD | 0.9/0.9 % | kas ketvirtį | LSE:0A9W |
Didžiausi Akcininkai
| Turėtojas | Dalis | Akcijos | Ataskaitos Data |
|---|---|---|---|
| Blackrock Inc. | 12.21% | 32.06 mln. | 2026-06-30 |
| Pentwater Capital Manage… | 6.89% | 18.1 mln. | 2026-06-30 |
| iShares Trust-iShares Co… | 6.09% | 16 mln. | 2026-08-31 |
| Vanguard Portfolio Manag… | 5.76% | 15.13 mln. | 2026-06-30 |
| Vanguard Capital Managem… | 4.54% | 11.91 mln. | 2026-06-30 |
| State Street Corporation | 3.68% | 9.66 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 8.33 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.29% | 6.02 mln. | 2026-06-30 |
| Goldman Sachs Group Inc | 1.98% | 5.2 mln. | 2026-06-30 |
| UBS Group AG | 1.85% | 4.86 mln. | 2026-06-30 |
| Geode Capital Management… | 1.83% | 4.82 mln. | 2026-06-30 |
| Alliancebernstein L.P. | 1.81% | 4.75 mln. | 2026-06-30 |
| Man Group PLC | 1.59% | 4.18 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.45% | 3.82 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 3.01 mln. | 2026-06-30 |
| NexPoint Funds I-NexPoin… | 1.03% | 2.71 mln. | 2026-06-30 |
| SPDR SERIES TRUST-State… | 0.94% | 2.47 mln. | 2026-08-31 |
| iShares Trust-iShares S&… | 0.89% | 2.35 mln. | 2026-08-31 |
| SPDR SERIES TRUST-State… | 0.54% | 1.41 mln. | 2026-08-31 |
| Fidelity Concord Street… | 0.49% | 1.3 mln. | 2026-07-31 |
| ALI KEVIN (Chief Executi… | ≈0.11% | 282 731 | 2025-05-05 |
| WALSH MATTHEW M (Chief F… | ≈0.08% | 212 746 | 2026-03-31 |
| MORRISSEY JOSEPH T JR (C… | ≈0.05% | 123 123 | 2026-03-31 |
| STAHLER RACHEL A (Chief… | ≈0.04% | 116 105 | 2026-03-31 |
| FALCIONE AARON (Officer) | ≈0.04% | 101 431 | 2026-03-31 |
| WEAVER KIRKE (General Co… | ≈0.04% | 92 639 | 2026-03-31 |
| NISITA VITTORIO (Officer… | ≈0.03% | 70 619 | 2026-03-31 |
| KARP DANIEL (Officer) | ≈0.03% | 69 547 | 2026-03-31 |
| HOLZBAUR LYNETTE (Office… | ≈0.02% | 52 850 | 2026-05-06 |
| COX CARRIE SMITH (Office… | — | — | 2025-11-12 |
